

Richard F Riedel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/197300/publications.pdf>

Version: 2024-02-01

94
papers

7,415
citations

126907

33
h-index

56724

83
g-index

98
all docs

98
docs citations

98
times ranked

9290
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1. <i>Journal of Clinical Oncology</i> , 2022, 40, 1291-1300.	1.6	24
2	Dual-Energy CT Vital Iodine Tumor Burden for Response Assessment in Patients With Metastatic GIST Undergoing TKI Therapy: Comparison With Standard CT and FDG PET/CT Criteria. <i>American Journal of Roentgenology</i> , 2022, 218, 659-669.	2.2	8
3	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	1.6	15
4	Evolving strategies for management of desmoid tumor. <i>Cancer</i> , 2022, 128, 3027-3040.	4.1	16
5	<i>sirolimus</i> for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.. <i>Journal of Clinical Oncology</i> , 2022, 40, 11574-11574.	1.6	2
6	Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2021, 26, e622-e631.	3.7	20
7	Recent advances in the understanding and management of liposarcoma. <i>Faculty Reviews</i> , 2021, 10, 1.	3.9	24
8	TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11500-11500.	1.6	13
9	Multiomic analysis to reveal distinct molecular profiles of uterine and nonuterine leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11555-11555.	1.6	2
10	P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11503-11503.	1.6	6
11	Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).. <i>Journal of Clinical Oncology</i> , 2021, 39, 11519-11519.	1.6	36
12	Large scale multiomic analysis suggests mechanisms of resistance to immunotherapy in leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11512-11512.	1.6	5
13	Results of NC-6300 (nanoparticle epirubicin) in an expansion cohort of patients with angiosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11543-11543.	1.6	1
14	Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. <i>Future Oncology</i> , 2021, 17, 2923-2939.	2.4	10
15	Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, , .	1.3	5
16	<i>sirolimus</i> for Patients With Malignant Perivascular Epithelioid Cell Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 3660-3670.	1.6	69
17	Individualizing systemic therapy for advanced soft tissue sarcomas based on tumor histology and biology. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 5-8.	2.4	5
18	Academic-Practice Partnership for Caregiver Training and Support. <i>North Carolina Medical Journal</i> , 2020, 81, 221-227.	0.2	3

#	ARTICLE	IF	CITATIONS
19	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARCO24 Study. <i>Oncologist</i> , 2020, 25, e1655-e1662.	3.7	13
20	A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 4225-4232.	7.0	22
21	Correlative Analyses of the SARCO28 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. <i>Clinical Cancer Research</i> , 2020, 26, 1258-1266.	7.0	115
22	Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT. <i>Journal of Clinical Oncology</i> , 2020, 38, 11516-11516.	1.6	14
23	A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304). <i>Journal of Clinical Oncology</i> , 2020, 38, 11562-11562.	1.6	4
24	NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1604-1612.	4.9	175
25	Enrollment barriers of adolescents and young adults (AYA) on the non-chemotherapy arm of ARST1321. <i>Journal of Clinical Oncology</i> , 2020, 38, e19214-e19214.	1.6	0
26	The experiences of older caregivers of cancer patients following hospital discharge. <i>Supportive Care in Cancer</i> , 2019, 27, 609-616.	2.2	9
27	Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1424-1431.	1.6	172
28	Recurrent Extradural Myxopapillary Ependymoma With Oligometastatic Spread. <i>Frontiers in Oncology</i> , 2019, 9, 1322.	2.8	11
29	Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration. <i>Lancet Oncology</i> , The, 2019, 20, 14-15.	10.7	2
30	Assessing the Impact of a Novel Integrated Palliative Care and Medical Oncology Inpatient Service on Health Care Utilization before Hospice Enrollment. <i>Journal of Palliative Medicine</i> , 2019, 22, 420-423.	1.1	5
31	ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 11005-11005.	1.6	20
32	A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1 ⁺ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival. <i>Journal of Clinical Oncology</i> , 2019, 37, 11011-11011.	1.6	10
33	Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARCO28 expansion cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 11015-11015.	1.6	65
34	Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. <i>Cancer</i> , 2018, 124, 3819-3829.	4.1	39
35	A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. <i>Oncologist</i> , 2018, 23, 782-790.	3.7	19
36	Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review. <i>Cancers</i> , 2018, 10, 417.	3.7	36

#	ARTICLE	IF	CITATIONS
37	Sorafenib for Advanced and Refractory Desmoid Tumors. <i>New England Journal of Medicine</i> , 2018, 379, 2417-2428.	27.0	287
38	Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 536-563.	4.9	457
39	A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11505-11505.	1.6	3
40	Phase 2 results of selinexor in advanced de-differentiated (DDLs) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11512-11512.	1.6	15
41	SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS11588-TPS11588.	1.6	16
42	Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS11589-TPS11589.	1.6	0
43	TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS11590-TPS11590.	1.6	1
44	Detection of endoglin-expressing CTCs in patients enrolled in an adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS).. <i>Journal of Clinical Oncology</i> , 2018, 36, e23570-e23570.	1.6	0
45	Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas. <i>F1000Research</i> , 2018, 7, 1737.	1.6	1
46	Phase I study of pazopanib plus TH-302 in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 611-619.	2.3	8
47	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1493-1501.	10.7	921
48	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , 2017, 171, 950-965.e28.	28.9	738
49	Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1089-1103.	10.7	214
50	Improvements in Patient and Health System Outcomes Using an Integrated Oncology and Palliative Medicine Approach on a Solid Tumor Inpatient Service. <i>Journal of Oncology Practice</i> , 2017, 13, e738-e748.	2.5	25
51	A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11005-11005.	1.6	30
52	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11008-11008.	1.6	32
53	Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.. <i>Journal of Clinical Oncology</i> , 2017, 35, 60-60.	1.6	3
54	Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 758-786.	4.9	239

#	ARTICLE	IF	CITATIONS
55	Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2016, 61, 94-101.	2.8	25
56	A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. <i>Science Translational Medicine</i> , 2016, 8, 320ra4.	12.4	224
57	Effects of enhanced caregiver training program on cancer caregiver's self-efficacy, preparedness, and psychological well-being. <i>Supportive Care in Cancer</i> , 2016, 24, 327-336.	2.2	118
58	Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028's A multicenter phase II study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11006-11006.	1.6	37
59	A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11016-11016.	1.6	15
60	The Selinexor in Advanced Liposarcoma (SEAL) study: A phase 2/3, multicenter, randomized, double blind study of selinexor versus placebo in patients with advanced, unresectable, dedifferentiated liposarcoma (DDLs).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS11072-TPS11072.	1.6	2
61	Defining the characteristics of medical oncology patients requiring inpatient hospital admission.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18023-e18023.	1.6	0
62	Healthcare utilization among cancer patients prior to hospice.. <i>Journal of Clinical Oncology</i> , 2016, 34, 135-135.	1.6	1
63	Rhabdomyosarcomatous Transformation of a Gastrointestinal Stromal Tumor following Treatment with Imatinib. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-5.	0.3	6
64	A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2015, 33, 10514-10514.	1.6	3
65	SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS10578-TPS10578.	1.6	12
66	Gastrointestinal Stromal Tumors, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 853-862.	4.9	96
67	Soft Tissue Sarcoma, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 473-483.	4.9	84
68	A phase I study of the safety and activation of a cathepsin-activatable fluorescent cancer-specific probe LUM015.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS11135-TPS11135.	1.6	3
69	Early palliative care on an inpatient oncology unit: Impact of a novel co-rounding partnership on patient and health system outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3-3.	1.6	8
70	Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2485-2492.	1.6	213
71	Oncologists's perceptions of rounding alongside palliative care physicians: Results of a post-intervention survey study.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20674-e20674.	1.6	1
72	Pathologic Complete Response of a Malignant Peripheral Nerve Sheath Tumor in the Lung Treated With Neoadjuvant Ifosfamide and Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, e291-e293.	1.6	12

#	ARTICLE	IF	CITATIONS
73	Soft Tissue Sarcoma, Version 2.2012. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 951-960.	4.9	117
74	Targeted Therapy in Sarcoma: Should We Be Lumpers or Splitters?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 652-657.	3.8	2
75	A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 70, 95-102.	2.3	40
76	Systemic therapy for advanced soft tissue sarcomas. Cancer, 2012, 118, 1474-1485.	4.1	33
77	Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (â‰¥ 24 months) overall survival results.. Journal of Clinical Oncology, 2012, 30, 10010-10010.	1.6	8
78	Targeted Agents for Sarcoma: Is Individualized Therapy Possible in Such a Diverse Tumor Type?. Seminars in Oncology, 2011, 38, S30-S42.	2.2	19
79	Emerging Therapeutic Targets for Soft Tissue Sarcoma. Current Oncology Reports, 2011, 13, 350-358.	4.0	3
80	Primary Meningeal Rhabdomyosarcoma. Sarcoma, 2011, 2011, 1-4.	1.3	12
81	NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-1-S-41.	4.9	1,004
82	Soft Tissue Sarcoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 630-674.	4.9	112
83	Characterizing the developmental pathways <i>TTF-1</i> , <i>NKX2â€“8</i> , and <i>PAX9</i> in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5312-5317.	7.1	50
84	The Clinical Management of Chondrosarcoma. Current Treatment Options in Oncology, 2009, 10, 94-106.	3.0	120
85	Cross Species Genomic Analysis Identifies a Mouse Model as Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma. PLoS ONE, 2009, 4, e8075.	2.5	71
86	A genomic approach to identify molecular pathways associated with chemotherapy resistance. Molecular Cancer Therapeutics, 2008, 7, 3141-3149.	4.1	64
87	Pharmacogenomic Strategies Provide a Rational Approach to the Treatment of Cisplatin-Resistant Patients With Advanced Cancer. Journal of Clinical Oncology, 2007, 25, 4350-4357.	1.6	98
88	A Phase II Trial of Carboplatin/Vinorelbine with Pegfilgrastim Support for the Treatment of Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 520-525.	1.1	9
89	Genomic signatures to guide the use of chemotherapeutics. Nature Medicine, 2006, 12, 1294-1300.	30.7	557
90	Thymoma: Benign Appearance, Malignant Potential. Oncologist, 2006, 11, 887-894.	3.7	62

#	ARTICLE	IF	CITATIONS
91	Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. <i>Journal of Thoracic Oncology</i> , 2006, 1, 692-6.	1.1	34
92	Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. <i>Future Oncology</i> , 2005, 1, 461-466.	2.4	6
93	Small-cell lung cancer: a review of clinical trials. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2003, 15, 448-456.	0.6	11
94	Expression of Constitutively Active Raf-1 in the Mitochondria Restores Antiapoptotic and Leukemogenic Potential of a Transformation-deficient BCR/ABL Mutant. <i>Journal of Experimental Medicine</i> , 1998, 187, 1995-2007.	8.5	94